Education
About Us
Working with TipRanks
Follow Us
SI-Bone Inc (SIBN)
NASDAQ:SIBN
SIBN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.70 - $20.05
Previous CloseN/A
Volume50.81K
Average Volume (3M)572.76K
Market Cap
$742.34M
Enterprise Value$483.86M
Total Cash (Recent Filing)$144.41M
Total Debt (Recent Filing)$37.15M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Aug 11, 2025EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding42,614,513
10 Day Avg. Volume545,735
30 Day Avg. Volume572,762
Financial Highlights & Ratios
PEG Ratio-4.46
Price to Book (P/B)4.73
Price to Sales (P/S)0.00
P/FCF Ratio-9.09
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue0.74
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda-4.69
Forecast
1Y Price Target
$24.29Price Target Upside39.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
SI-Bone News
PremiumCompany Announcements
SI-Bone Concludes Annual Meeting with Key Approvals
PremiumCompany Announcements
SI-BONE Earnings Call: Strong Growth Amid Challenges
Bulls Say, Bears Say
Bulls Say
EarningsSIBN delivered strong top- and bottom-line results, including impressive year-over-year growth in active surgeons and surgeons performing more than one procedure type.
Product LaunchThe launches of its Granite 9.5 and TNT product have exceeded expectations, showing promising engagement with interventional spine doctors.
Regulatory ApprovalSIBN has received FDA Breakthrough Device Designation for its new Pelvic Fracture Fixation System, exceeding launch expectations and making SIBN the only public company in its industry granted three BDDs.
Bears Say
Market PressuresDespite market pressures, SIBN is considered to be in good standing, with a target multiple maintained at ~3x (EV/26E revenue) implying a price target of $19.
Ownership Overview
5.06% Insiders
29.48% Mutual Funds
41.38% Other Institutional Investors
12.76% Public Companies and
Individual Investors
SIBN FAQ
What was SI-Bone Inc’s price range in the past 12 months?
SI-Bone Inc lowest stock price was $11.70 and its highest was $20.05 in the past 12 months.
What is SI-Bone Inc’s market cap?
SI-Bone Inc’s market cap is $742.34M.
When is SI-Bone Inc’s upcoming earnings report date?
SI-Bone Inc’s upcoming earnings report date is Aug 11, 2025 which is in 56 days.
How were SI-Bone Inc’s earnings last quarter?
SI-Bone Inc released its earnings results on May 05, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.226 by $0.076.
Is SI-Bone Inc overvalued?
According to Wall Street analysts SI-Bone Inc’s price is currently Undervalued.
Does SI-Bone Inc pay dividends?
SI-Bone Inc does not currently pay dividends.
What is SI-Bone Inc’s EPS estimate?
SI-Bone Inc’s EPS estimate is -0.18.
How many shares outstanding does SI-Bone Inc have?
SI-Bone Inc has 42,614,513 shares outstanding.
What happened to SI-Bone Inc’s price movement after its last earnings report?
SI-Bone Inc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.226. Following the earnings report the stock price went up 15.439%.
Which hedge fund is a major shareholder of SI-Bone Inc?
Currently, no hedge funds are holding shares in SIBN
SI-Bone Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.29 (39.44% Upside)
$24.29 (39.44% Upside)
Blogger Sentiment
Bullish
SIBN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 124.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $621.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.35%
12-Months-Change
Fundamentals
Return on Equity
-15.96%
Trailing 12-Months
Asset Growth
1.59%
Trailing 12-Months
Company Description
SI-Bone Inc
SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
SIBN Company Deck
SIBN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, increased physician engagement, and improved gross margins, but also acknowledged challenges such as ongoing net losses, slow international revenue growth, and pending regulatory decisions. The overall sentiment is cautiously optimistic with strong operational performance but mindful of external conditions.Read More>SIBN Stock 12 Month Forecast
Average Price Target
$24.29
▲(39.44%Upside)